Pfizer, Inc. (NYSE:PFE) has been given a $39.00 target price by investment analysts at Jefferies Group LLC in a research note issued on Thursday. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target suggests a potential upside of 10.29% from the company’s current price.

A number of other research firms also recently weighed in on PFE. Deutsche Bank AG set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 10th. Barclays PLC set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $38.48.

Pfizer (PFE) opened at $35.36 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market capitalization of $210,889.83, a P/E ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer has a 1-year low of $30.51 and a 1-year high of $36.78.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 EPS. analysts anticipate that Pfizer will post 2.6 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/16/jefferies-group-llc-analysts-give-pfizer-inc-pfe-a-39-00-price-target.html.

In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the sale, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 374,621 shares of company stock valued at $12,796,098. 0.06% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northstar Group Inc. grew its stake in Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 35 shares in the last quarter. Peregrine Asset Advisers Inc. lifted its holdings in shares of Pfizer by 0.5% in the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares during the last quarter. Northwest Quadrant Wealth Management LLC lifted its holdings in shares of Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares during the last quarter. River Wealth Advisors LLC lifted its holdings in shares of Pfizer by 0.3% in the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 55 shares during the last quarter. Finally, Meridian Wealth Management LLC increased its stake in Pfizer by 0.5% during the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 57 shares during the period. 69.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.